<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02855268</url>
  </required_header>
  <id_info>
    <org_study_id>ACT16248</org_study_id>
    <secondary_id>2019-004394-10</secondary_id>
    <nct_id>NCT02855268</nct_id>
  </id_info>
  <brief_title>Study of Lademirsen (SAR339375) in Patients With Alport Syndrome</brief_title>
  <acronym>HERA</acronym>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        -  To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal&#xD;
           function&#xD;
&#xD;
        -  To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport&#xD;
           syndrome&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To assess plasma pharmacokinetic (PK) parameters of the parent compound and its&#xD;
           metabolites&#xD;
&#xD;
        -  To assess the potential formation of anti-drug antibodies (ADAs) following&#xD;
           administration of lademirsen (SAR339375)&#xD;
&#xD;
        -  To assess the pharmacodynamic effect of lademirsen (SAR339375) on miR-21 and on changes&#xD;
           in renal injury and function biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The planned length of participation in the study for each subject is up to approximately 110&#xD;
      weeks (from screening through completion of follow-up). This includes:&#xD;
&#xD;
        -  Screening/baseline period of up to 4 weeks&#xD;
&#xD;
        -  Double-blind, placebo-controlled treatment period of 48 weeks&#xD;
&#xD;
        -  Open-label extension treatment period of 48 weeks ( all subject to enter a 48-week open&#xD;
           label extension period and receive active treatment with lademirsen (SAR339375))&#xD;
&#xD;
        -  Post-treatment follow-up period of 10 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2019</start_date>
  <completion_date type="Anticipated">December 4, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 4, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Baseline to maximum 106 weeks</time_frame>
    <description>Number of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized change in estimated glomerular filtration rate eGFR from baseline</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Annualized change in estimated glomerular filtration rate eGFR from baseline to 48 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) : Maximum concentration in plasma (Cmax)</measure>
    <time_frame>24 weeks and 48 weeks</time_frame>
    <description>Plasma concentrations (Cmax) of lademirsen (SAR339375), RG0005, and sum of lademirsen (SAR339375) and RG0005 (SUM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) : Trough plasma concentration (Ctrough)</measure>
    <time_frame>24 weeks, 48 weeks and 96 weeks</time_frame>
    <description>Plasma concentrations (Ctrough) of sum of lademirsen (SAR339375) and RG0005 (SUM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with anti-drug antibodies (ADAs)</measure>
    <time_frame>Baseline to maximum 106 weeks</time_frame>
    <description>Number of participants with ADAs incidents and titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participant with adverse events associated to ADAs</measure>
    <time_frame>Baseline to maximum 106 weeks</time_frame>
    <description>Association of ADAs with adverse events per participants will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in eGFR values</measure>
    <time_frame>Baseline to 24 weeks, 48 weeks and 96 weeks</time_frame>
    <description>Percent change in eGFR values from baseline to 24 weeks and 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who reach end staged renal disease (ESRD)</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Proportion of participants who reach ESRD as defined by an eGFR ≤15 mL/min/1.73 m^2 or initiation of hemodialysis or renal transplantation from baseline to 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a reduction from baseline in eGFR</measure>
    <time_frame>Baseline to Weeks 24, 48, and 96</time_frame>
    <description>Proportion of subjects with a reduction from baseline in eGFR of &lt;10%, &lt;20%, &lt;30%, or &lt;40% reduction at Week 24, 48 and 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating miR-21</measure>
    <time_frame>Weeks 24, 48, and 96</time_frame>
    <description>Change of circulating miR-21 from baseline to 24 weeks, 48 weeks and 96 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood urea nitrogen</measure>
    <time_frame>Baseline to Weeks 24, 48, and 96</time_frame>
    <description>Change in blood urea nitrogen from baseline to 24 weeks, 48 weeks and 96 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in protein/creatinine ratio and albumin/creatinine ratio in urine only</measure>
    <time_frame>Baseline to Weeks 24, 48, and 96</time_frame>
    <description>Change in protein/creatinine ratio and albumin/creatinine ratio in urine only from baseline to 24 weeks, 48 weeks and 96 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in epidermal growth factor (EGF) in urine only</measure>
    <time_frame>Baseline to Weeks 24, 48, and 96</time_frame>
    <description>Change in EFG from baseline to 24 weeks, 48 weeks and 96 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in creatinine in both blood and urine</measure>
    <time_frame>Baseline to Weeks 24, 48, and 96</time_frame>
    <description>Change in ceatinine from baseline to 24 weeks, 48 weeks and 96 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cystatin C in both blood and urine</measure>
    <time_frame>Baseline to Weeks 24, 48, and 96</time_frame>
    <description>Change in Cystatin C from baseline to 24 weeks, 48 weeks and 96 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in transforming growth factor-β (TGF-β) in both blood and urine</measure>
    <time_frame>Baseline to Weeks 24, 48, and 96</time_frame>
    <description>Change in TGF-β from baseline to 24 weeks, 48 weeks and 96 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in neutrophil gelatinase-associated lipocalin (NGAL) in both blood and urine</measure>
    <time_frame>Baseline to Weeks 24, 48, and 96</time_frame>
    <description>Change in NGAL from baseline to 24 weeks, 48 weeks and 96 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Alport's Syndrome</condition>
  <arm_group>
    <arm_group_label>lademirsen (SAR339375)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will receive subcutaneous injection every week for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible participants will receive subcutaneous injection every week for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lademirsen (SAR339375)</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection</description>
    <arm_group_label>lademirsen (SAR339375)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Confirmed diagnosis of Alport syndrome&#xD;
&#xD;
               1. Clinical diagnosis (hematuria, family history, hearing loss, ocular change), AND&#xD;
&#xD;
               2. Genetic confirmation of Alport Syndrome in the subject or the family member, OR&#xD;
&#xD;
               3. Kidney biopsy showing glomerular basement membrane abnormalities (eg, significant&#xD;
                  thinning, thickening, irregularity or lucencies) consistent with Alport Syndrome.&#xD;
&#xD;
          -  Age 18-55 years old&#xD;
&#xD;
          -  eGFR &gt; 35 ml/min/1.73m^2 and &lt;90 mL/min/1.73m^2 (based on CKD-EPI) at screening&#xD;
&#xD;
          -  Renal Function Criteria (patients must meet at least one of the following CRITERIA A,&#xD;
             B or C):&#xD;
&#xD;
               -  A)Decline in eGFR of ≥4 mL/min/1.73 m^2/year (eGFR slope &lt;= -4) based on a linear&#xD;
                  regression slope analysis of ≥4 eGFR measurements within 3 years prior to the&#xD;
                  study and with a minimum of 2-year time span (the last, of the screening&#xD;
                  measurement, and first eGFR measurements should be separated by at least 2&#xD;
                  years). eGFR should be calculated by using either the Chronic Kidney Disease&#xD;
                  Epidemiology Collaboration (CKD-EPI) creatinine equation.&#xD;
&#xD;
               -  B) proteinuria (UPCR) &gt;2000 mg/g (UACR&gt;1000 mg/g)&#xD;
&#xD;
               -  C) Age and sex adjusted eGFR (based on CKD-Epi; male 18-23 eGFR&lt;90 mL/min/1.73m^2&#xD;
&#xD;
          -  ACE inhibitor and/or ARB, the dosing regimen should be stable for at least 30 days&#xD;
             prior to screening&#xD;
&#xD;
          -  Sexually active female subjects of childbearing potential and sexually mature male&#xD;
             subjects must agree to practice true abstinence in line with their preferred and usual&#xD;
             lifestyle or to use two acceptable effective methods of contraception for the entire&#xD;
             duration of the study and for at least 6 weeks after last dose.&#xD;
&#xD;
          -  Negative drug screen for opiates, cocaine, heroin, phencyclidine, amphetamines&#xD;
             (including ecstasy), barbiturates, benzodiazepines, and cannabinoids. At the&#xD;
             Investigator's discretion, subjects prescribed benzodiazepines, cannabinoids, or&#xD;
             opiates with positive results on a drug screen may be allowed.&#xD;
&#xD;
          -  Negative screening results for hepatitis B surface antigen (HBsAg), hepatitis C virus&#xD;
             (HCV) antibody, and human immunodeficiency virus (HIV) antibody&#xD;
&#xD;
          -  Normal biological tests&#xD;
&#xD;
          -  Able to understand all study procedures in the informed consent form (ICF) and willing&#xD;
             to comply with all aspects of the protocol&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Causes of chronic kidney disease aside from Alport syndrome (including but not limited&#xD;
             to other heritable disorders leading to chronic kidney disease, diabetic nephropathy,&#xD;
             hypertensive nephropathy, lupus nephritis, IgA nephropathy)&#xD;
&#xD;
          -  ESRD as evidenced by ongoing dialysis therapy or history of renal transplantation&#xD;
&#xD;
          -  Any clinically significant illness within 30 days before screening or surgical or&#xD;
             medical condition (other than Alport syndrome) that could interfere with the subject's&#xD;
             study compliance; confound the study results; impact subject safety; or significantly&#xD;
             alter the absorption, distribution, metabolism, or excretion of drugs.&#xD;
&#xD;
          -  Weight &gt; 110 kg&#xD;
&#xD;
          -  Any history of active malignancy within the last 1 year (history of localized basal&#xD;
             cell or squamous cell carcinoma and cervical carcinoma in situ that has been&#xD;
             excised/appropriately treated or a fully excised malignant lesion with a low&#xD;
             probability of recurrence will not be considered exclusionary)&#xD;
&#xD;
          -  Prior treatment with Bardoxolone within 90 days prior to screening&#xD;
&#xD;
          -  History or presence of alcoholism or drug abuse within 2 years before screening or&#xD;
             other concurrent social conditions that would potentially interfere with the subject's&#xD;
             study compliance, at the discretion of the Investigator&#xD;
&#xD;
          -  Participation in a recent investigational study and receipt of an investigational drug&#xD;
             or investigational use of a licensed drug within 30 days or 5 half lives, whichever is&#xD;
             longer, prior to screening&#xD;
&#xD;
          -  History or presence of hypersensitivity or idiosyncratic, allergic, or other&#xD;
             clinically significant reaction to the study drug (including placebo), inactive&#xD;
             ingredients, or related compounds (eg, other oligonucleotide products)&#xD;
&#xD;
          -  Any other condition or circumstance that, in the opinion of the Investigator, may make&#xD;
             the subject unlikely to complete the study or comply with study procedures and&#xD;
             requirements, or may pose a risk to the subject's safety and well-being&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number :8400002</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400003</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400004</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400001</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400005</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0360003</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0360001</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0360002</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1240003</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H1V8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1560001</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1560002</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1560004</name>
      <address>
        <city>Guangzhou</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2500001</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2500002</name>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2760002</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2760001</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240005</name>
      <address>
        <city>Cordoba</city>
        <state>Andalucia</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240001</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240004</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240002</name>
      <address>
        <city>Madrid / Madrid</city>
        <state>Madrid, Comunidad De</state>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240003</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8260001</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8260002</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8260003</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>August 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2016</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney disease</keyword>
  <keyword>Nephritis</keyword>
  <keyword>Hereditary nephritis</keyword>
  <keyword>Hereditary kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis, Hereditary</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

